These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

700 related articles for article (PubMed ID: 22481232)

  • 1. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy.
    Pataer A; Kalhor N; Correa AM; Raso MG; Erasmus JJ; Kim ES; Behrens C; Lee JJ; Roth JA; Stewart DJ; Vaporciyan AA; Wistuba II; Swisher SG;
    J Thorac Oncol; 2012 May; 7(5):825-32. PubMed ID: 22481232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy.
    William WN; Pataer A; Kalhor N; Correa AM; Rice DC; Wistuba II; Heymach J; Lee JJ; Kim ES; Munden R; Gold KA; Papadimitrakopoulou V; Swisher SG; Erasmus JJ;
    J Thorac Oncol; 2013 Feb; 8(2):222-8. PubMed ID: 23287849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should patients with stage IB non-small cell lung cancer receive adjuvant chemotherapy? A comparison of survival between the 8th and 7th editions of the AJCC TNM staging system for stage IB patients.
    Wang J; Wu N; Lv C; Yan S; Yang Y
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):463-469. PubMed ID: 30474757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival analysis in advanced non small cell lung cancer treated with platinum based chemotherapy in combination with paclitaxel, gemcitabine and etoposide.
    Natukula K; Jamil K; Pingali UR; Suresh Attili VS; Naidu Madireddy UR
    Asian Pac J Cancer Prev; 2013; 14(8):4661-6. PubMed ID: 24083721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A retrospective study: platinum-based induction chemotherapy combined with gemcitabine or paclitaxel for stage IIB-IIIA central non-small-cell lung cancer.
    Lv C; Ma Y; Wu N; Yan S; Zheng Q; Sun Y; Li S; Fang J; Yang Y
    World J Surg Oncol; 2013 Mar; 11():76. PubMed ID: 23517534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery.
    Santarpia M; Ramirez JL; de Aguirre I; Garrido P; Pérez Cano M; Queralt C; Gonzalez-Larriba JL; Insa A; Provencio M; Isla D; Camps C; Blanco R; Moran T; Rosell R;
    Clin Lung Cancer; 2017 Mar; 18(2):178-188.e4. PubMed ID: 27908619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.
    Yang KL; Chang YC; Ko HL; Chi MS; Wang HE; Hsu PS; Lin CC; Yeh DY; Kao SJ; Jiang JS; Chi KH
    Clin Lung Cancer; 2016 Nov; 17(6):550-557. PubMed ID: 27378175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neo-adjuvant chemo/immunotherapy in the treatment of stage III (N2) non-small cell lung cancer: a phase I/II pilot study.
    Ratto GB; Costa R; Maineri P; Alloisio A; Piras MT; D'Agostino A; Tripodi G; Rivabella L; Dozin B; Bruzzi P; Melioli G
    Int J Immunopathol Pharmacol; 2011; 24(4):1005-16. PubMed ID: 22230406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.
    Machtay M; Lee JH; Stevenson JP; Shrager JB; Algazy KM; Treat J; Kaiser LR
    J Thorac Cardiovasc Surg; 2004 Jan; 127(1):108-13. PubMed ID: 14752420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of clinical efficacy of three different neoadjuvant approaches (chemotherapy combined vaginal intracavitary irradiation, neoadjuvant chemotherapy alone or radiotherapy) combined with surgery for patients with stage Ib2 and IIa2 cervical cancer.
    Fu JH; Gao Z; Ren CC; Shi YG
    Asian Pac J Cancer Prev; 2013; 14(4):2377-81. PubMed ID: 23725144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma.
    Qu Y; Emoto K; Eguchi T; Aly RG; Zheng H; Chaft JE; Tan KS; Jones DR; Kris MG; Adusumilli PS; Travis WD
    J Thorac Oncol; 2019 Mar; 14(3):482-493. PubMed ID: 30503889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant gemcitabine and carboplatin followed by immediate cystectomy may be associated with a survival benefit in patients with clinical T2 bladder cancer.
    Koie T; Ohyama C; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y
    Med Oncol; 2014 May; 31(5):949. PubMed ID: 24700028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.
    Liao WY; Chen JH; Wu M; Shih JY; Chen KY; Ho CC; Yang JC; Yu CJ
    Clin Lung Cancer; 2013 Jul; 14(4):418-24. PubMed ID: 23291258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor cavitation in patients with stage III non-small-cell lung cancer undergoing concurrent chemoradiotherapy: incidence and outcomes.
    Phernambucq EC; Hartemink KJ; Smit EF; Paul MA; Postmus PE; Comans EF; Senan S
    J Thorac Oncol; 2012 Aug; 7(8):1271-5. PubMed ID: 22659960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemotherapy with gemcitabine-containing regimens in patients with early-stage non-small cell lung cancer.
    Detterbeck FC; Socinski MA; Gralla RJ; Edelman MJ; Jahan TM; Loesch DM; Limentani SA; Govindan R; Zaman MB; Ye Z; Monberg MJ; Obasaju CK
    J Thorac Oncol; 2008 Jan; 3(1):37-45. PubMed ID: 18166839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of gemcitabine-carboplatin-paclitaxel as neoadjuvant chemotherapy for operable non-small cell lung cancer.
    Abratt RP; Lee JS; Han JY; Tsai CM; Boyer M; Mok T; Kim SW; Lee JS; Brnabic AJ; Reece WH; Lehnert M
    J Thorac Oncol; 2006 Feb; 1(2):135-40. PubMed ID: 17409842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II multicenter trial with carboplatin and gemcitabine induction chemotherapy followed by radiotherapy concomitantly with low-dose paclitaxel and gemcitabine for stage IIIA and IIIB non-small cell lung cancer.
    Hirsh V; Soulieres D; Duclos M; Faria S; Del Vecchio P; Ofiara L; Ayoub JP; Charpentier D; Gruber J; Portelance L; Souhami L
    J Thorac Oncol; 2007 Oct; 2(10):927-32. PubMed ID: 17909355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gender, Age, and Comorbidity Status Predict Improved Survival with Adjuvant Chemotherapy Following Lobectomy for Non-small Cell Lung Cancers Larger than 4 cm.
    Sandler BJ; Wang Z; Hancock JG; Boffa DJ; Detterbeck FC; Kim AW
    Ann Surg Oncol; 2016 Feb; 23(2):638-45. PubMed ID: 26474557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is neoadjuvant chemotherapy followed by radical surgery more effective than radiation therapy for stage IIB cervical cancer?
    Lee DW; Lee KH; Lee JW; Park ST; Park JS; Lee HN
    Int J Gynecol Cancer; 2013 Sep; 23(7):1303-10. PubMed ID: 23881101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of induction high-dose chemotherapy followed by surgical resection and radiation therapy for patients with marginally resectable non-small cell carcinoma of the lung.
    Schilder RJ; Goldberg M; Millenson MM; Movsas B; Rogatko A; Rogers B; Langer CJ
    Lung Cancer; 2000 Jan; 27(1):37-45. PubMed ID: 10672782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.